Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Oct;10(5):605-614.
doi: 10.1007/s40271-017-0232-1.

Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial)

Maria Patrizia Carrieri  1   2 , Camelia Protopopescu  3   4 , Zobair Younossi  5 , Antoine Vilotitch  1   2 , Hélène Fontaine  6   7 , Ventzislava Petrov-Sanchez  8 , Fabienne Marcellin  1   2 , Fabrice Carrat  9   10 , Christophe Hézode  11 , Marc Bourlière  12 ; CUPIC Study Group
Collaborators, Affiliations
Free article
Clinical Trial

Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial)

Maria Patrizia Carrieri et al. Patient. 2017 Oct.
Free article

Abstract

Objective: We aimed to compare health-related quality of life (HRQL) during and after hepatitis C virus (HCV) treatment in patients receiving pegylated-interferon (PEG-IFN)-containing therapy (including boceprevir or telaprevir-ANRS CO20 CUPIC cohort) who subsequently switched to PEG-IFN-free regimens (sofosbuvir + ledipasvir with or without ribavirin [RBV]-SIRIUS trial).

Methods: Two analyses were performed. The first compared physical (PCS) and mental (MCS) HRQL (MOS SF-12) scores during treatment between CUPIC and SIRIUS. The second compared PCS and MCS scores after treatment end between CUPIC and SIRIUS. The analyses used linear regression mixed models adjusted for pre-treatment HRQL scores, gender, and age at each visit.

Results: Among patients enrolled successively in both studies, 43 (corresponding to 212 HRQL assessments) and 43 (82 HRQL assessments) were eligible for the 'during' and 'post' treatment analyses, respectively. In the 'during-treatment' analysis, we found significantly higher PCS and MCS values during PEG-IFN-free treatment than for PEG-IFN-containing treatment. In the 'post-treatment' analysis, results showed significantly higher MCS values after PEG-IFN-free treatment than after PEG-IFN-containing treatment. No significant difference was found for PCS in the post-treatment analysis.

Conclusions: These results highlight an improvement in both physical and mental HRQL during HCV treatment, but no major improvement in physical HRQL after treatment end, when comparing PEG-IFN-free regimens with PEG-IFN-containing regimens. This suggests that in the PEG-IFN-free regimens era, screening and comprehensive care of comorbidities and residual somatic symptoms during treatment, and especially after HCV clearance, are still needed to improve patient outcomes.

Keywords: Mental Component Summary; Mental Component Summary Score; Physical Component Summary; Sustained Virologic Response; Telaprevir.

PubMed Disclaimer

References

    1. Ann Med. 2001 Jul;33(5):350-7 - PubMed
    1. Lancet Infect Dis. 2015 Apr;15(4):397-404 - PubMed
    1. Am J Ther. 2009 Nov-Dec;16(6):573-8 - PubMed
    1. J Hepatol. 2013 Sep;59(3):434-41 - PubMed
    1. J Viral Hepat. 2011 Sep;18(9):619-27 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources